Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Invex Therapeutics Ltd

IXC.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.08

▲ +0.00%

Market Cap $6.10M · Vol 6.25K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.10M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

N/A

YoY

RSI (14)

25.00

Momentum

Beta

0.55

vs Market

52W High

$0.13

31.43% below

52W Low

$0.06

65.94% above

Volume

6.25K

Avg 16.57K

P/B

1.27

Price-to-book

ROE

N/A

Return on equity

Free Float

36.07%

Public shares

Shariah Compliance8 STANDARDS

✗ Invex Therapeutics Ltd (IXC.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IXC.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

+9.52%

-8.00%

+4.55%

YTD

-4.17%

+53.33%

+175.10%

-28.36%

Financials & Valuation

TTM · Annual

Total Revenue	$303.68K
Net Income	$-313,780.00
Revenue Growth (YoY)	+10.19%
Gross Margin	100.00%
Operating Margin	-103.33%
Net Profit Margin	-103.33%
ROE	N/A
ROA · ROIC	-8.23% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	14.49
P/B	1.27
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	75.15M

Technical Indicators

50-Day SMA	$0.08
200-Day SMA	$0.08
RSI (14)	25.00
Beta	0.55
52-Week High	$0.13
52-Week Low	$0.06

Volume Today	6.25K
Avg Daily Volume (30D)	16.57K
Relative Volume	0.38x
Volatility (10D)	21.09
Volatility (30D)	66.14
Free Float	36.07%

Analyst Consensus

N/A

Current Price $0.08

Mean Target N/A

52W Low$0.06 52W High$0.13

Current

Target

$0.06 $0.13

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00PD615Z5

ISINAU0000048621

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on the repurposing of an already-approved drug, Exenatide, for the efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP). In addition, the Company has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. The principal activity of the Company is the development of Exenatide, including generating new pre-clinical data in Alzheimer’s Disease (AD) under a collaboration with Tessara Therapeutics. The Company has trademarked its repurposed Exenatide as Presendin. The Company is focused on managing the close out of the Phase III Idiopathic Intracranial Hypertension (IIH) EVOLVE clinical trial and explore new potential applications for Exenatide in TBI and other neurological disorders with raised ICP, consistent with its patents.